相似文献
1
Biotech's wellspring: the health of private biotech in 2012.
Nat Biotechnol. 2013 May;31(5):396-403. doi: 10.1038/nbt.2577.
2
2006: a stellar year for financing.
Nat Biotechnol. 2007 Feb;25(2):156. doi: 10.1038/nbt0207-156.
3
Biotech's wellspring-a survey of the health of the private sector in 2015.
Nat Biotechnol. 2016 Jun 9;34(6):608-15. doi: 10.1038/nbt.3600.
4
The rise of European venture capital for biotechnology.
Nat Biotechnol. 2003 Nov;21(11):1287-91. doi: 10.1038/nbt1103-1287.
5
VC funding hits high in Q1.
Nat Biotechnol. 2007 May;25(5):496. doi: 10.1038/nbt0507-496.
6
Mixed results in Q1.
Nat Biotechnol. 2005 May;23(5):518. doi: 10.1038/nbt0505-518.
7
Does biotech M&A benefit investors?
Nat Biotechnol. 2004 Sep;22(9):1085. doi: 10.1038/nbt0904-1085.
8
IPOs break $1 billion in Q2.
Nat Biotechnol. 2007 Aug;25(8):833. doi: 10.1038/nbt0807-833.
9
Crystal gazing: biotech's financial outlook: the biotech analyst's view.
Nat Biotechnol. 2006 Mar;24(3):261-2. doi: 10.1038/nbt0306-261a.
10
Biotech's wellspring--a survey of the health of the private sector in 2014.
Nat Biotechnol. 2015 May;33(5):470-7. doi: 10.1038/nbt.3218.
本文引用的文献
1
Biotech's wellspring: a survey of the health of the private sector.
Nat Biotechnol. 2012 May 7;30(5):395-400. doi: 10.1038/nbt.2209.
Zotero 插件